Publications

Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern

Garg R, Liu Q, Van Kessel J, et al. Vaccine. Published online May 14, 2024. doi:10.1016/j.vaccine.2024.05.028

Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE

Xu S, Duan H, An Y, et al. Vaccine. 2023;41(17):2793-2803. doi:10.1016/j.vaccine.2023.03.035

Enhancing Immunogenicity of a Thermostable, Efficacious SARS-CoV-2 Vaccine Formulation through Oligomerization and Adjuvant Choice

Khan MS, Jakob V, Singh R, et al. Published online December 12, 2023. doi:10.3390

Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms

Reinke S, Pantazi E, Chappell GR, et al. Cell Reports Medicine. Published online October 2023:101245. doi:10.1016/j.xcrm.2023.101245

Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen

Doss-Gollin S, Thomas S, Brook B, et al. npj Vaccines. 2023;8(1):163. doi:10.1038/s41541-023-00759-y

OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model

Primard C, Monchâtre-Leroy E, Del Campo J, et al. Front Immunol. 2023;14:1188605. doi:10.3389/fimmu.2023.1188605

Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model.

Ludwig J, Scally SW, Costa G, et al. npj Vaccines. 2023;8(1):52. doi:10.1038/s41541-023-00653-7

Enhanced Protective Efficacy of a Novel, Thermostable, RBD-S2 Fusion Immunogen against SARS-CoV-2 and Its Variants

Mittal N, Kumar S, Rajmani RS, et al. Biophysics; 2023. doi:10.1101/2023.03.19.533338

Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE

Xu S, Duan H, An Y, et al. Vaccine. Published online March 2023:S0264410X23003195. doi:10.1016/j.vaccine.2023.03.035

Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.

Su J, Brunner L, Oz EA, et al. Journal of Hepatology. Published online January 2023:S0168827822034651. doi:10.1016/j.jhep.2022.12.013

Meeting vaccine formulation challenges in an emergency setting: towards the development of accessible vaccines.

Peletta A, Lemoine C, Courant T, Collin N, Borchard G. Pharmacological Research. Published online February 14, 2023:106699. doi:10.1016/j.phrs.2023.106699

Designing Adjuvant Formulations to Promote Immunogenicity and Protective Efficacy of Leptospira Immunoglobulin-Like Protein A Subunit Vaccine

Techawiwattanaboon T, Courant T, Brunner L, et al. D. Front Cell Infect Microbiol. 2022;12:918629. doi:10.3389/fcimb.2022.918629

Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine

O’Donnell JS, Isaacs A, Jakob V, et al. Front Immunol. 2022;13. Accessed October 7, 2022. https://www.frontiersin.org/articles/10.3389/fimmu.2022.976968

Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.

Su J, Brunner L, Oz EA, et al. Journal of Hepatology. Published online January 2023:S0168827822034651. doi:10.1016/j.jhep.2022.12.013

Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses

McMillan CLD, Cheung STM, Modhiran N, et al. npj Vaccines. 2021;6(1):135. doi:1038/s41541-021-00395-4

Better Pandemic Influenza Preparedness through Adjuvant Technology Transfer: Challenges and Lessons Learned

Lemoine CH, Nidom RV, Ventura R, et al. Vaccines. 2021;9(5):461. doi:3390/vaccines9050461

Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice

Dalvie NC et al. Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):e2106845118. doi: 10.1073/pnas.2106845118

The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration

Janitzek CM, Carlsen PHR, Thrane S, et al. Vaccines. 2021;9(2):131. doi:10.3390/vaccines9020131

Vaccine-Induced Th1-Type Response Protects against Invasive Group A Streptococcus Infection in the Absence of Opsonizing Antibodies

Rivera-Hernandez et al. (2020). mBio. 2020 Mar 10;11(2):e00122-20. doi: 10.1128/mBio.00122-20.PMID: 32156809

Modulation of immune responses using adjuvants to facilitate therapeutic vaccination

Schijns V, Fernández‐Tejada A, Barjaktarović Ž, et al. Immunol Rev. 2020;296(1):169-190. doi:1111/imr.12889

Technological Approaches for Improving Vaccination Compliance and Coverage

Lemoine, C. et al. (2020). Vaccines (Basel). 2020 Jun 16;8(2):304. doi: 10.3390/vaccines8020304. PMID: 32560088

H7N9 Influenza Split Vaccine With SWE Oil-In-Water Adjuvant Greatly Enhances Cross-Reactive Humoral Immunity and Protection Against Severe Pneumonia in Ferrets

De Jonge et al. (2020). NPJ Vaccines. 2020 May 11;5:38. doi: 10.1038/s41541-020-0187-4. eCollection 2020.PMID: 32411401

Efficacy of three innovative bacterin vaccines against experimental infection with Mycoplasma hyopneumoniae

Matthijs AMF et al. (2019). Vet Res. 2019 Nov 8;50(1):91. doi: 10.1186/s13567-019-0709-0. PubMed PMID: 31703726; PubMed Central PMCID: PMC6842239.

Electroporation of a nanoparticle-associated DNA vaccine induces higher inflammation and immunity compared to its delivery with microneedle patches in pigs

Bernelin-Cottet et al. (2019). J Control Release. 2019 Aug 28;308:14-28. doi: 10.1016/j.jconrel.2019.06.041. Epub 2019 Jun 29.PMID: 31265882

Reduced Renal Colonization and Enhanced Protection by Leptospiral Factor H Binding Proteins as a Multisubunit Vaccine Against Leptospirosis in Hamsters

Techawiwattanaboon et al. (2019). Vaccines (Basel). 2019 Aug 22;7(3):95. doi: 10.3390/vaccines7030095.PMID: 31443566

A DNA-Modified Live Vaccine Prime–Boost Strategy Broadens the T-Cell Response and Enhances the Antibody Response against the Porcine Reproductive and Respiratory Syndrome Virus

Bernelin-Cottet et al. (2019). Viruses. 2019 Jun 14;11(6):551. doi: 10.3390/v11060551.PMID: 31207934

Equitable realization of the right to health in Haiti: how household data inform health seeking behavior and financial risk protection

Cros M et al. (2019). Int J Equity Health. 2019 May 27;18(1):77. doi: 10.1186/s12939-019-0973-7.PMID: 31133035

Systems Immunology Characterization of Novel Vaccine Formulations for Mycoplasma hyopneumoniae Bacterins.

Matthijs AMF et al. (2019). Front Immunol. 2019 May 24;10:1087. doi: 10.3389/fimmu.2019.01087. eCollection 2019.PMID: 31178860

Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus

Marcandalli J et al. (2019). Cell. 2019 Mar 7;176(6):1420-1431.e17. doi: 10.1016/j.cell.2019.01.046. PubMed PMID: 30849373.

A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis

Wang C et al. (2018). PLoS Negl Trop Dis. 2018 Oct 29;12(10):e0006870. doi: 10.1371/journal.pntd.0006870. eCollection 2018 Oct.PMID: 30372438.

System immunology-based identification of blood transcriptional modules correlating to antibody responses in sheep

Braun RO et al. (2019). NPJ Vaccines. 2018 Oct 3;3:41. doi: 10.1038/s41541-018-0078-0. eCollection 2018.PMID: 30302283

Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation

Younis, S.Y. et al. (2018). BMC Immunol. 2018 Jan 31;19(1):6. doi: 10.1186/s12865-018-0245-0.PMID: 29386070.

The anti-influenza M2e antibody response is promoted by XCR1 targeting in pig skin

Deloizy, C. et al. (2017). Sci Rep. 2017 Aug 9;7(1):7639. doi: 10.1038/s41598-017-07372-9.PMID: 28794452.

Accounting for adjuvant-induced artifacts in the characterization of vaccine formulations by polyacrylamide gel electrophoresis

Jakob V. et al. (2017). Ther Adv Vaccines. 2017 Apr;5(2):31-38. doi: 10.1177/2051013617702072. Epub 2017 May 3.PMID: 28515938.

Exacerbated Leishmaniasis Caused by a Viral Endosymbiont can be Prevented by Immunization with Its Viral Capsid

Castiglioni, P. et al. (2017). PLoS Negl Trop Dis. 2017 Jan 18;11(1):e0005240. doi: 10.1371/journal.pntd.0005240. eCollection 2017 Jan.PMID: 28099431.

Ag85A DNA Vaccine Delivery by Nanoparticles: Influence of the Formulation Characteristics on Immune Responses

Poecheim, J. et al. (2016). Vaccines (Basel). 2016 Sep 12;4(3):32. doi: 10.3390/vaccines4030032.PMID: 27626449.

QS-21 Adjuvant: Laboratory-Scale Purification Method and Formulation into Liposomes

Brunner L, Barnier-Quer C, Collin N. (2016). Methods Mol Biol. 2017;1494:73-86. doi: 10.1007/978-1-4939-6445-1_5.PMID: 27718186.

Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles

Varypataki E.M. et al. (2016). J Control Release. 2016 Mar 28;226:98-106. doi: 10.1016/j.jconrel.2016.02.018. Epub 2016 Feb 11.PMID: 26876760.

SALO, a novel classical pathway complement inhibitor from saliva of the sand fly Lutzomyia longipalpis

Ferreira VP et al (2016). Sci Rep. 2016 Jan 13;6:19300. doi: 10.1038/srep19300.PMID: 26758086.

Nanocarriers for DNA Vaccines: Co-Delivery of TLR-9 and NLR-2 Ligands Leads to Synergistic Enhancement of Proinflammatory Cytokine Release

Poecheim J et al. (2015). Nanomaterials (Basel). 2015Dec17;5(4):2317-2334.doi:10.3390/nano5042317.PMID: 28347123.

TRANSVAC research infrastructure – Results and lessons learned from the European network of vaccine research and development

Geels, MJ., et al. (2015). Vaccine. 2015 Oct 5;33(41):5481-5487. doi: 10.1016/j.vaccine.2015.01.079. Epub 2015 Feb 8.PMID: 25667962.

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development

Kaufmann, SHE et al. (2017). Front Immunol. 2017 Oct 4;8:1203. doi: 10.3389/fimmu.2017.01203. eCollection 2017.PMID: 29046674.

Modern Vaccines/Adjuvants Formulation-Session 2 (Plenary II): May 15-17, 2013-Lausanne, Switzerland

Collin, N. (2013). Hum Vaccin Immunother. 2013 Sep;9(9):2015-6. doi: 10.4161/hv.26208.Epub2013Aug20.PMID: 23966098.

Fate of TLR-1/ TLR-2 agonist functionalized pDNA nanoparticles upon deposition at the human bronchial epithelium in vitro

Heuking, S., et al. (2013). J Nanobiotechnology. 2013 Aug 21;11:29. doi:10.1186/1477-3155-11-29.PMID: 23964697.

Publications

VFI headquarters and Geneva laboratories

VFI Lausanne laboratories